Drug-coated Balloon for Peripheral Artery Diseases Market Share, Size [2032]

Report Description

Drug-coated Balloon for Peripheral Artery Diseases Market Outlook 2032

The drug-coated balloon for peripheral artery diseases market size was USD 1.2 Billion in 2023 and is projected to reach USD 2.6 Billion by 2032, expanding at a CAGR of 9.1% during 2024–2032.

As a result, the segment is witnessing a gradual shift with some healthcare providers opting for SCBs as a safer alternative, especially in patients with higher risks of restenosis or those who are sensitive to paclitaxel.

Get Free Sample Report

The segment expansion for SCBs is likely hinge on the outcomes of head-to-head studies comparing their efficacy and safety to PCBs, which can potentially reshape market dynamics and influence prescribing patterns in the treatment of peripheral artery diseases.

Drug-coated Balloon for Peripheral Artery Diseases Market Dynamics

Get Free Sample Report

Drivers           

The increasing prevalence of PAD worldwide, which is fueled by rising rates of diabetes, obesity, and other lifestyle-related diseases drives the market. As these conditions escalate, particularly in aging populations, the demand for effective and minimally invasive treatment options such as DCBs grows.

DCBs offer significant advantages over traditional treatments such as standard balloon angioplasty and stenting, including reduced rates of restenosis and the need for repeat revascularization procedures. This clinical efficacy is a major driver in their adoption.

The advancements in medical technology that enhance the performance and safety of DCBs propels the market. Improved drug formulations and coating technologies ensure better drug retention and more effective delivery to the target lesion, which enhances patient outcomes. Additionally, the growing body of clinical evidence supporting the benefits of DCBs in various vascular interventions further encourages their adoption among healthcare providers.

Restraints

The cost associated with DCB procedures, which can be significantly higher than traditional angioplasty. This cost factor can limit the adoption of DCBs, particularly in cost-sensitive markets and among patients without adequate insurance coverage.

Regulatory hurdles also pose significant restraints. The approval process for medical devices, including DCBs, can be lengthy and rigorous, particularly in regions with stringent regulatory frameworks like the US and Europe. The need for extensive clinical data to demonstrate safety and efficacy can delay product launches and increase development costs.

Opportunities

The rapid growth of the market, particularly in emerging markets where the prevalence of PAD is rising but current penetration of advanced treatments such DCBs is low, creates new opportunities the market. Countries in Asia Pacific, Latin America, and parts of Eastern Europe present significant growth opportunities as healthcare infrastructure improves and awareness of advanced PAD treatments increases.Innovation and technological advancements also present substantial opportunities.

The development of next-generation DCBs with enhanced drug formulations, better patient safety profiles, and improved efficacy can help overcome current market restraints and meet the needs of a broader patient population. Additionally, the exploration of new therapeutic applications for DCBs in other vascular and non-vascular fields could expand the market considerably.

Scope of the Drug-coated Balloon for Peripheral Artery Diseases Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Drug-coated Balloon for Peripheral Artery Diseases Market Segment Insights

Product Type Segment Analysis

Paclitaxel-coated balloons (PCBs) segment dominates the drug-coated balloon for peripheral artery diseases market. These balloons are widely recognized for their efficacy in preventing restenosis, which is the re-narrowing of arteries post-treatment.

The growth of the segment is driven by their successful outcomes in clinical settings and strong endorsements by healthcare professionals globally. The growth is fueled by increasing incidences of PAD coupled with the aging population susceptible to vascular diseases. For instance,

• According to the American Heart Association Journals, Atherosclerotic lower extremity peripheral artery disease (PAD) is increasingly recognized as a cause of cardiovascular morbidity and mortality that affects nearly more the 230 million people worldwide.

Recent developments in the PCB market include advancements in balloon technology that enhance drug transfer and retention, aiming to improve patient outcomes further. Manufacturers are focusing on innovations that minimize paclitaxel loss during transit and deployment to the lesion site, which can enhance the therapeutic efficacy of the treatment. Looking ahead, the future outlook for paclitaxel-coated balloons appears promising.

The growth of the segment, particularly in regions with rising healthcare standards and accessibility to advanced medical treatments. Continued clinical research and development are expected to further validate the long-term benefits of PCBs, potentially leading to broader acceptance and usage in the treatment of peripheral artery diseases.

Sirolimus-coated balloons (SCBs) segment is gaining significant traction in the market, due to their potential benefits over paclitaxel-coated alternatives. Sirolimus-coated balloons offer a different pharmacological approach, with sirolimus known for its potent antiproliferative properties without the associated cytotoxic effects seen with paclitaxel. This characteristic is particularly appealing in the context of safety profiles, where concerns regarding paclitaxel’s long-term effects continue to be scrutinized.

Get Free Sample Report

End-user Segment Analysis

Hospitals holds a major share of the drug-coated balloon for peripheral artery diseasesmarket, due to the comprehensive care facilities, including advanced vascular surgery capabilities, that hospitals offer. The demand for DCBs in hospitals is driven by the increasing prevalence of PAD among the aging population and the rising incidence of diabetes and obesity, which are significant risk factors for PAD.

Hospitals are typically equipped with specialized vascular departments and interventional radiology units that facilitate the use of high-end medical devices such as DCBs. Hospitals are influenced by factors such as the availability of skilled healthcare professionals, reimbursement policies, and the integration of new technologies.

The adoption of DCBs in hospitals is further supported by favorable reimbursement scenarios in many developed countries, where insurers recognize the cost-effectiveness and clinical benefits of DCB treatments over traditional therapies.

As hospitals continue to upgrade their technological capabilities and expand their service offerings, the demand for advanced therapeutic options like DCBs is expected to grow. This trend is particularly evident in urban areas and developed regions, where healthcare infrastructure is robust, driving the overall market growth for DCBs.

The Ambulatory Surgical Centers (ASCs) segment is gaining significant traction in the market, primarily due to their cost-efficiency and patient convenience. ASCs offer a viable alternative to hospitals for performing outpatient procedures, including those involving DCBs, which do not require long hospital stays. The growth factors for DCBs in ASCs include shorter wait times for patients, lower risk of hospital-acquired infections, and reduced procedural costs compared to inpatient hospital settings.

These factors make ASCs particularly attractive to patients and insurance providers alike. The market potential for DCBs in ASCs is substantial, as these centers are increasingly being equipped to handle more complex procedures that traditionally required hospitalization. This shift is supported by advancements in medical technology and surgical techniques that allow for safe and effective treatment of PAD in an outpatient setting.

Additionally, the growing focus on cost containment in healthcare is prompting payers to favor procedures performed in ASCs over more expensive hospital settings. As regulatory frameworks continue to evolve and support outpatient care models, ASCs are expected to see significant growth in the use of DCBs, further expanding their role in the management of peripheral artery diseases.

Get Free Sample Report

Regional Analysis

North America dominates the global market for drug-coated balloons (DCBs) for peripheral artery diseases (PAD), driven by a combination of advanced healthcare infrastructure, high healthcare expenditure, and a strong presence of key market players. The United States, in particular, dominates the regional market due to its robust medical device industry and significant investments in research and development.

The market size in North America is substantial, reflecting a high prevalence of PAD among the aging population and lifestyle-related risk factors such as diabetes and obesity.Trends in the North American DCB market include a growing preference for minimally invasive procedures and a rapid adoption of new and advanced technologies. This region has seen a swift uptake of the latest generations of DCBs, supported by favorable clinical trial data and endorsements from medical associations.

The market in the Europe is anticipated to witness the fastest growth in the market during the forecast period, influenced by a comprehensive regulatory landscape. The market in the Europe is characterized by stringent regulations governed by the European Medicines Agency (EMA) and other regulatory bodies, which ensure the safety and efficacy of medical devices.

The regulatory landscape in Europe is currently undergoing significant changes with the introduction of the Medical Device Regulation (MDR) 2017/745, which aims to enhance transparency and oversight of medical devices. This new regulation is expected to impact the market, with manufacturers needing to comply with more rigorous clinical evaluation and post-market surveillance requirements.

Get Free Sample Report